Prognostic Value of ctDNA in Hepatocellular Carcinoma: A Meta-Analysis

Post-operative detection of circulating tumour DNA (ctDNA) signals a 4.48-fold increase in the risk of disease recurrence (95% CI 2.56-7.82). This stark statistic illustrates the urgent need to integrate ctDNA in hepatocellular carcinoma management. While curative-intent treatments remove visible lesions, occult minimal residual disease often escapes detection by conventional imaging, leading to high relapse rates.

Why Measuring ctDNA in Hepatocellular Carcinoma Matters

The analysis of 793 patients across ten studies reveals a consistent pattern: molecular residue predicts clinical failure. Beyond recurrence, overall survival is compromised in patients with persistent ctDNA (HR 2.99; 95% CI 1.94-4.61). Even baseline detection—prior to surgical intervention—serves as a strong negative prognosticator for recurrence-free survival (HR 3.54). These hazard ratios represent a significant deviation from outcomes seen in ctDNA-negative cohorts.

The data suggests that plasma biomarkers act as a highly specific alarm system. Specificity in the analysed studies reached as high as 100%, meaning false positives are rare. However, sensitivity varied significantly (33-82%), likely due to methodological heterogeneity across different laboratories. This variability indicates that while the signal is accurate when found, a negative result does not effectively rule out residual disease.

Implications for Clinical Practice

Current surveillance protocols react to macroscopic tumour growth. In contrast, liquid biopsies proactively identify microscopic persistence. The robustness of these findings, confirmed by leave-one-out analyses, supports the design of prospective trials where adjuvant therapy is guided by molecular status rather than anatomical staging alone. If standardisation issues are resolved, this biomarker could redefine 'remission' from a visual assessment to a molecular certainty.